H. G. Davies, R. J. Richter, M. Keifer, C. A. Broomfield, J. Sowalla et al., The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin, Nat Genet, vol.14, pp.334-340, 1996.

A. Tward, Y. R. Xia, X. P. Wang, Y. S. Shi, C. Park et al.,

, Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice, Circulation, vol.106, pp.484-90, 2002.

M. I. Mackness, S. Arrol, and P. N. Durrington, Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein, FEBS Lett, vol.286, p.307, 1991.

J. Perla-kaján and H. Jakubowski, Paraoxonase 1 protects against protein Nhomocysteinylation in humans, FASEB J, vol.24, pp.931-937, 2010.

O. Rozenberg, D. M. Shih, and M. Aviram, Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation, Arterioscler Thromb Vasc Biol, vol.23, pp.461-468, 2003.

R. J. Richter and C. E. Furlong, Determination of paraoxonase (PON1) status requires more than genotyping, Pharmacogenetics, vol.9, pp.745-753, 1999.

S. P. Deakin and R. W. James, Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1, Clin Sci, vol.107, pp.435-482, 2004.

H. Soran, N. N. Younis, V. Charlton-menys, and P. Durrington, Variation in paraoxonase-1 activity and atherosclerosis, Curr Opin Lipidol, vol.20, pp.265-74, 2009.

S. Deakin, I. Leviev, S. Guernier, and R. W. James, Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2, Arterioscler Thromb Vasc Biol, vol.23, issue.13, pp.2083-2092, 2003.

A. Nagila, T. Permpongpaiboon, S. Tantrarongroj, P. Porapakkham, K. Chinwattana et al., Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status, Pharmacol Rep, vol.61, pp.892-900, 2009.

C. Gouédard, N. Koum-besson, R. Barouki, and Y. Morel, Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins, Mol Pharmacol, vol.63, pp.945-56, 2003.

R. Barouki, X. Coumoul, and P. M. Fernandez-salguero, The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein, FEBS Lett, vol.581, pp.3608-3623, 2007.
URL : https://hal.archives-ouvertes.fr/hal-02175734

C. Gouédard, R. Barouki, and Y. Morel, Dietary polyphenols increase paraoxonase 1

, gene expression by an aryl hydrocarbon receptor-dependent mechanism, Mol Cell Biol, vol.24, pp.5209-5231, 2004.

P. Jaichander, K. Selvarajan, M. Garelnabi, and S. Parthasarathy, Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin, J Lipid Res, vol.49, pp.2142-2150, 2008.

S. Pierre, A. S. Bats, A. Chevallier, L. C. Bui, A. Ambolet-camoit et al.,

M. Aggerbeck, R. Barouki, and X. Coumoul, Induction of the Ras activator Son of Sevenless 1 by environmental pollutants mediates their effects on cellular proliferation, Biochem Pharmacol, vol.81, pp.304-317, 2011.
URL : https://hal.archives-ouvertes.fr/hal-02190082

M. Widerak, C. Ghoneim, M. F. Dumontier, M. Quesne, M. T. Corvol et al.,

, The aryl hydrocarbon receptor activates the retinoic acid receptoralpha through SMRT antagonism, Biochimie, vol.88, pp.387-97, 2006.

K. Arii, T. Suehiro, Y. Ikeda, Y. Kumon, M. Inoue et al.,

K. Hashimoto and Y. Terada, Role of protein kinase C in pitavastatin-induced human paraoxonase I expression in Huh7 cells, Metabolism, vol.59, pp.1287-93, 2010.

M. Garige, M. Gong, R. Varatharajalu, and M. R. Lakshman,

, sterol responsive element-like sequence in paraoxonase 1 promoter in HuH7 liver cells, Metabolism, vol.59, pp.1372-1378, 2010.

C. Gouédard, R. Barouki, and Y. Morel, Induction of the paraoxonase-1 gene expression by resveratrol, Arterioscler Thromb Vasc Biol, vol.24, pp.2378-83, 2004.

J. A. Baur and D. A. Sinclair, Therapeutic potential of resveratrol: the in vivo evidence

, Nat Rev Drug Discov, vol.5, pp.493-506, 2006.

J. A. Baur, K. J. Pearson, N. L. Price, H. A. Jamieson, C. Lerin et al.,

J. S. Allard, G. Lopez-lluch, K. Lewis, P. J. Pistell, S. Poosala et al., Resveratrol improves health and survival of mice on a high-calorie diet, Nature, vol.444, pp.337-379, 2006.

M. Lagouge, C. Argmann, Z. Gerhart-hines, H. Meziane, C. Lerin et al.,

N. Messadeq, J. Milne, P. Lambert, P. Elliott, B. Geny et al., Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha, Cell, vol.127, pp.1109-1131, 2006.
URL : https://hal.archives-ouvertes.fr/hal-00188005

J. L. Bowers, V. V. Tyulmenkov, S. C. Jernigan, and C. M. Klinge, Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta, Endocrinology, vol.141, pp.3657-67, 2000.

A. Revel, H. Raanani, E. Younglai, J. Xu, I. Rogers et al.,

. Rf, Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects lung from DNA damage and apoptosis caused by benzo[a]pyrene, J Appl Toxicol, vol.23, pp.255-61, 2003.

S. U. Singh, R. F. Casper, P. C. Fritz, B. Sukhu, B. Ganss et al.,

H. C. Tenenbaum, Inhibition of dioxin effects on bone formation in vitro by a newly described aryl hydrocarbon receptor antagonist, resveratrol, J Endocrinol, vol.167, pp.183-95, 2000.

R. F. Casper, M. Quesne, I. M. Rogers, T. Shirota, A. Jolivet et al.,

, Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity, Mol Pharmacol, vol.56, p.15, 1999.

A. Cirla and J. Mann, Combretastatins: from natural products to drug discovery, Nat Prod Rep, vol.20, pp.558-64, 2003.

J. Khateeb, A. Gantman, A. J. Kreitenberg, M. Aviram, and B. Fuhrman,

, PON1) expression in hepatocytes is upregulated by pomegranate polyphenols: a role for PPAR-gamma pathway, Atherosclerosis, vol.208, pp.119-144, 2010.

F. Osaki, Y. Ikeda, T. Suehiro, K. Ota, S. Tsuzura et al., Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells, Atherosclerosis, vol.176, pp.279-287, 2004.

S. Safe and A. Mcdougal, Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers (Review), Int J Oncol, vol.20, pp.1123-1131, 2002.

I. A. Murray, J. L. Morales, C. A. Flaveny, B. C. Dinatale, C. Chiaro et al.,

S. Amin and G. H. Perdew, Evidence for ligand-mediated selective modulation of aryl hydrocarbon receptor activity, Mol Pharmacol, vol.77, pp.247-54, 2010.